⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
OCS News
Oculis Holding AG Ordinary shares
Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis’ Position as an Emerging Leading Neuro-Ophthalmology Company
globenewswire.com
OCS
Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis’ Position as an Emerging Leading Neuro-Ophthalmology Company
globenewswire.com
OCS
Oculis Reports Q2 2026 Financial Results and Provides Company Update
globenewswire.com
OCS
Oculis Reports Q2 2026 Financial Results and Provides Company Update
globenewswire.com
OCS
Oculis Reports Q2 2026 Financial Results and Provides Company Update
globenewswire.com
OCS
Oculis Reports Q2 2026 Financial Results and Provides Company Update
globenewswire.com
OCS
Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses
globenewswire.com
OCS
Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses
globenewswire.com
OCS
Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference
globenewswire.com
OCS
Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference
globenewswire.com
OCS